GEN-MKT-18-7897-A
Dec 1, 2015 | Blogs, Life Science Research, Proteomics | 0 comments
SWATH® Acquisition: On the Forefront of HIV-1 Research
World AIDS Day is held on the 1st December each year and is an opportunity for people worldwide to unite in the fight against HIV, show their support for people living with HIV, and to commemorate people who have died. World AIDS Day was the first ever global health day, held for the first time in 1988.
Source: http://www.worldaidsday.org/about
A research team at the University of Nebraska Medical Center (UNMC) is using SWATH Acquisition to advance a host-oriented antiviral strategy that targets the biomolecules required for viral replication.
Using SWATH for quantitative proteomics together with bioinformatic analyses to identify host proteins, the team quantified the expression of 3,608 proteins in uninfected and HIV-1-infected monocyte-derived microphages.
Of these, they found that 420 were significantly altered upon HIV-1 infection, and the findings highlighted a novel set of proteins and processes that are involved in the host response to HIV-1 infection.
Journal of Proteomics Research, 2014, April 4; Drs. P. Ciborowski, N. Haverland, H. Fox, University of Nebraska Medical Center or VIEW the webinar (May 2014) by Drs. Pawel Ciborowski and Nicole Haverland
In this informative presentation, you’ll learn:
The Echo® MS+ system is a novel platform for Acoustic Ejection Mass Spectrometry (AEMS) and combines the speed of acoustic sampling with the selectivity of mass spectrometry. This platform has been designed for high throughput analysis of small and large molecules. The technology combines Acoustic Droplet Ejection (ADE), an Open Port Interface (OPI) and could be coupled with the SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system.
The Echo® MS+ system comprises of an open-port interface (OPI) and acoustic droplet ejection (ADE) module which could be coupled with a mass spectrometer. The mass spectrometer could either be a SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system. This non-liquid chromatography based; high-throughput screening platform enables rapid analysis of compounds at speeds of up to 1 sample/second.
The ability to consistently achieve reproducible results on many complex samples across multiple days is critical to a routine clinical laboratory. Laboratories relying on analytical instrumentation require stability and robustness to perform a variety of screening and confirmatory assays with confidence. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become the preferred analytical method in the clinical laboratory to reliably perform clinical testing as it provides best-in-class performance and reliability for the most challenging assays. LC-MS/MS offers the required levels of sensitivity and specificity for the detection and quantitation of molecules from complex biological samples, helping laboratories deliver highly accurate data for a variety of clinically relevant analytes across a wide range of assays.
Posted by
You must be logged in to post a comment.
Share this post with your network